MELVILLE, N.Y.--(BUSINESS WIRE)--Aug. 7, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - News) announced today its financial results for the second quarter of 2006. The Company reported total revenues of $102.0 million for the three months ended June 30, 2006, an increase of $67.3 million (or 194%) compared to revenues of $34.6 million for the same period last year. Revenues increased $164.7 million (or 307%) to $218.4 million for the six months ended June 30, 2006 compared to revenue of $53.7 million for the same period last year. The increase was primarily due to the growth in revenues arising from worldwide Tarceva® (erlotinib) sales, and the addition of Macugen® (pegaptanib sodium injection)-related revenue streams. Total worldwide net sales of Tarceva reported by the Company's collaborators for Tarceva, Genentech, Inc. and Roche, were $157 million and $289 million for the three and six months ended June 30, 2006, respectively. Total U.S. Macugen sales were $36.7 million and $87.2 million for the three and six months ended June 30, 2006, respectively.
